Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 49, Issue 12

Issues

Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance

Aldo Clerico / Simona Vittorini / Claudio Passino
Published Online: 2011-08-26 | DOI: https://doi.org/10.1515/CCLM.2011.686

Abstract

Recent studies demonstrated that large amounts of the pro-hormone peptide of brain natriuretic peptide (proBNP) can be detected in plasma of healthy subjects and in particular of patients with heart failure. As a result, a great part of B-type natriuretic peptides measured in patients with cardio-vascular disease may be devoid of biological activity. These findings stimulated the set up of specific immunoassay methods for the measurement of the intact proBNP peptide. The aim of this review article is to discuss the methodological characteristics and the possible clinical relevance of specific immunoassay methods for the measurement of the proBNP peptide. From an analytical point of view, a fully automated immunoassay of proBNP has some theoretical advantages (e.g., a more stable molecule with higher molecular weight than the derived peptides) compared to the active hormone BNP. Recent studies supported the concept that the precursor proBNP might be actually considered a circulating prohormone, which can be cleaved by specific plasma proteases in BNP, the active hormone, and NT-proBNP, an inactive peptide. The peripheral processing of circulating proBNP could likely be submitted to regulatory rules, which might be impaired in patients with heart failure, opening new perspectives in the treatment of heart failure (e.g., by studying drugs inducing the cleavage of the prohormone into active BNP). Furthermore, as a future perspective, the specific assay in the same plasma sample of the intact precursor proBNP and of the biologically active peptide BNP, could allow a more accurate estimation of the production/secretion of B-type related peptides from cardiomyocytes and of the global cardiac endocrine function.

Keywords: brain type natriuretic peptide (BNP); cardiac endocrine function; corin; heart failure; immunoassay

About the article

Corresponding author: Prof. Aldo Clerico, MD, Department of Laboratory Medicine, Fondazione G. Monasterio CNR-Regione Toscana, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy Phone: +39-0585-493569, Fax: +39-0585-493652


Received: 2011-05-09

Accepted: 2011-07-26

Published Online: 2011-08-26

Published in Print: 2011-12-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 49, Issue 12, Pages 1949–1954, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.686.

Export Citation

©2011 by Walter de Gruyter Berlin Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Rogerio da Hora Passos, Juliana Caldas, Joao Gabriel Rosa Ramos, Erica Batista dos Santos Galvão de Melo, Michel Por Deus Ribeiro, Maria Fernanda Coelho Alves, Paulo Benigno Pena Batista, Octavio Henrique Coelho Messeder, Augusto Manoel de Carvalho de Farias, Etienne Macedo, and Jean Jacques Rouby
Critical Care, 2019, Volume 23, Number 1
[2]
Malik Benmachiche, Pedro Marques-Vidal, Gérard Waeber, Marie Méan, and Vincenzo Lionetti
PLOS ONE, 2018, Volume 13, Number 11, Page e0207118
[3]
Gianfranco Cervellin and Salvatore di Somma
Clinical Chemistry and Laboratory Medicine (CCLM), 2012, Volume 50, Number 9
[4]
Aldo Clerico, Claudio Passino, Maria Franzini, and Michele Emdin
Future Cardiology, 2016, Volume 12, Number 5, Page 573
[5]
Otto A. Sanchez, David R. Jacobs, Hossein Bahrami, Carmen A. Peralta, Lori B. Daniels, João A. Lima, Alan Maisel, and Daniel A. Duprez
Journal of Hypertension, 2015, Volume 33, Number 5, Page 966
[6]
Aldo Clerico, Maria Franzini, Silvia Masotti, Concetta Prontera, and Claudio Passino
Critical Reviews in Clinical Laboratory Sciences, 2015, Volume 52, Number 2, Page 56
[7]
Yujean Lee, Hyori Kim, and Junho Chung
Experimental & Molecular Medicine, 2014, Volume 46, Number 9, Page e114
[8]
Salvatore Di Somma, Francesco Vetrone, and Alan S. Maisel
Current Emergency and Hospital Medicine Reports, 2014
[9]
D. Gruson, M. Mancini, S.A. Ahn, and M.F. Rousseau
Clinica Chimica Acta, 2014, Volume 429, Page 189
[10]
Damien Gruson, Thibault Lepoutre, Sylvie A. Ahn, and Michel F. Rousseau
Peptides, 2013, Volume 50, Page 125
[11]
Silvia Del Ry, Manuela Cabiati, and Aldo Clerico
Pharmacological Research, 2013, Volume 76, Page 190
[12]
Aldo Clerico, Martina Zaninotto, Concetta Prontera, Stefania Giovannini, Rudina Ndreu, Maria Franzini, Gian Carlo Zucchelli, and Mario Plebani
Clinica Chimica Acta, 2012, Volume 414, Page 112
[13]
D. R. Woods, J. Begley, M. Stacey, C. Smith, C. J. Boos, T. Hooper, A. Hawkins, P. Hodkinson, N. Green, and A. Mellor
Acta Physiologica, 2012, Volume 205, Number 3, Page 349

Comments (0)

Please log in or register to comment.
Log in